Imidazoquinoxaline Src-Family Kinase p56Lck Inhibitors: SAR, QSAR, and the Discovery of (S)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a Potent and Orally Active Inhibitor with Excellent in Vivo Antiinflammatory Activity
摘要:
A series of novel anilino 5-azaimidazoquinoxaline analogues possessing potent in vitro activity against p56(Lck) and T cell proliferation have been discovered. Subsequent SAR studies led to the identification of compound 4 (BMS-279700) as an orally active lead candidate that blocks the production of proinflammatory cytokines (IL-2 and TNFalpha) in vivo. In addition, an expanded set of imidazoquinoxalines provided several descriptive QSAR models highlighting the influence of significant steric and electronic features. The H-bonding (Met319) contribution to observed binding affinities within a tightly congeneric series was found to be significant.
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase
申请人:Bristol-Myers Squibb Co.
公开号:US05990109A1
公开(公告)日:1999-11-23
Novel heterocyclo-substituted imidazopyrazines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.
HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:EP1066286B1
公开(公告)日:2009-04-29
Epoxy hardener systems based on aminomethylene-ethyleneureas
申请人:Schile D. Richard
公开号:US20070179257A1
公开(公告)日:2007-08-02
An epoxy-hardener system is provided having relatively long latency periods combined with relatively short cure times at low cure temperatures. The hardeners of the present invention are ureidoamines and their derivatives, which are chelates of ureido compounds and amines. The ureidoamines are prepared by reacting an amine with the ureido compound and aqueous formaldehyde without a catalyst. Complexes of ureidoamine hardeners with various blocking agents are prepared in the melt. The hardener is prevented from curing the epoxy by the reaction between the hardener and the blocking agent. The blocked hardener is then blended with the epoxy, usually by warming the mixture briefly at about 50-60 degrees C.
Methods for matrix cleanup and analysis of drugs and metabolites in biological matrices
申请人:Yang Yuhui
公开号:US20080050838A1
公开(公告)日:2008-02-28
The invention is directed to the use of weak anion exchange (WAX) materials for trapping of negative and zwitterionic interfaces from biological matrices, and then reduction of the biological matrix effect in the quantitative analysis process of basic and neutral compounds present in the matrix. The sample preparation process includes adding the WAX cleanup step before or after or during the conventional extraction procedures like liquid-liquid extraction, protein precipitation, solid phase extraction and others. Such a step greatly enhances the selectivity of the extraction process via the removal of the majority of the contaminants and reduces the matrix effect in the quantitative analysis. In addition, the WAX-enhanced extraction is very simple versatile, rug and easy to be operated.